Recent news on Treprostinil

United Therapeutics Reports First Quarter 2007 Financial Results  -  May 1, 2007
PharmaLive.com (press release),During the first quarter of 2006, we purchased and expensed advanced chemical intermediates for the manufacture of oral treprostinil.

New Strategies for Pulmonary Arterial Hypertension: Evaluation and ...  -  Apr 23, 2007
Medscape (subscription)Drugs attempting to correct the prostacyclin deficiency underlying PAH are the prostanoids (epoprostenol, treprostinil, and iloprost).

United Therapeutics and Mochida Pharmaceutical Sign Remodulin ...  -  Mar 29, 2007
Drug Newswire (press release),Ltd. announced today that the companies have signed an agreement for the exclusive distribution in Japan of Remodulin(R) (treprostinil sodium) Injection

Intravenous Treprostinil Linked to Higher Rate of Bloodstream ...  -  Mar 2, 2007
Medscape (subscription)Both medications are administered primarily at home; benefits of treprostinil over the older drug epoprostenol include a longer half-life (4 hours vs 3-6

Intravenous treprostinil linked to increased rates of bloodstream ...  -  Mar 2, 2007
Therapeutics Daily (subscription) (press release),Only two prostanoids are approved for use in the US, epoprostenol (Flolan) and treprostinil. The CDC supervised a retrospective investigation for 2003 to

Study Raises Questions For United Therapeutics  -  Feb 26, 2007
Washington Post,United Therapeutics sells the prostacyclin treprostinil under the trade name Remodulin. The warning came in reaction to a recent presentation by the Centers

United Therapeutics Volume Heavy on Data  -  Feb 26, 2007
Houston Chronicle,Silver Spring, Md.-based United Therapeutics sells the prostacyclin treprostinil under the trade name Remodulin. The guidance came in reaction to a recent

United Therapeutics Announces Pulmonary Hypertension Opinion ...  -  Feb 27, 2007
Medical News Today (press release),...among patients treated with intravenous epoprostenol and intravenous treprostinil for pulmonary arterial hypertension, United States 2004 - 2006".

United Therapeutics Announces Pulmonary Hypertension Opinion ...  -  Feb 26, 2007
Earthtimes.org...fully describe the known infection risk and appropriate technique that should be practiced when preparing and administering intravenous treprostinil.

Results of Inhaled Treprostinil Controlled Pilot Studies Reported ...  -  Feb 13, 2007
Drug Newswire (press release),Lung Rx also announced today that the name VIVETA has been submitted to the FDA as the proposed brand name for Treprostinil Sodium for Inhalation.

Market Report -- In Play (UTHR)  -  Feb 1, 2007
MSN Money...in pulmonary arterial hypertension patients with subcutaneous treprostinil; and Rapid Switch from intravenous epoprostenol to intravenous treprostinil

United Therapeutics Reports 2006 Annual Financial Results  -  Feb 20, 2007
PR Newswire (press release),The increase was primarily due to (i) an increase in expenses for treprostinil-related programs of approximately $12.9 million, (ii) an increase in expenses

Improved Long-Term Outcome With Remodulin Reported in European ...  -  Feb 1, 2007
PR Newswire (press release),Long-term outcome in pulmonary arterial hypertension patients with subcutaneous treprostinil. (Eur Respir J 2006:1195-1203); and Rapid Switch from

Improved Long-Term Outcome With Remodulin Reported in European ...  -  Feb 1, 2007
DG News...of two important studies: Long-term outcome in pulmonary arterial hypertension patients with subcutaneous treprostinil (Eur Respir J 2006:1195-1203);

Improved Long-Term Outcome With Remodulin Reported in European ...  -  Feb 1, 2007
PR Newswire (press release),...(Eur Respir J 2006:1195-1203); and Rapid Switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.

Specialty Infusion Brings New Challenges, Solutions to Payers  -  Feb 12, 2007
Atlantic Information Services, Inc.,...under which drugs such as Remicade (infliximab), Novantrone (mitoxantrone), Flolan (epoprostenol sodium) and Remodulin (treprostinil sodium) fall.

(PRN) - Great Spring UK Travel Deals Starting at $450 Roundtrip on ...  -  Feb 8, 2007
Bolsamania.com,...(PRN) - Results of Inhaled Treprostinil Controlled Pilot Studies Reported in the Journal of the American College Of Cardiology ... [+]

United Therapeutics Affiliate Initiates First-Ever Gene-Therapy ...  -  Dec 13, 2006
PipelineReview.com (press release),...have been enrolled in its TRIUMPH-1 trial, a 200-patient 12-week placebo-controlled trial of inhaled treprostinil in pulmonary arterial hypertension.

Treprostinil Treatment Appears to Improve Health of Pulmonary ...  Oct 26, 2006
SALT LAKE CITY, UT -- October 26, 2006 -- Patients can handle safely be treated for up to 1 year with subcutaneous treprostinil (Remodulin) for pulmonary ... -DG News Results Of Inhaled Treprostinil Study Reported In The Journal Of ...  Oct 11, 2006
...a wholly owned subsidiary of United Therapeutics Corporation (Nasdaq: UTHR), announced the publication of "Safety and Efficacy of Inhaled Treprostinil as Add ... -Medical News Today (press release), Results of Inhaled Treprostinil Study Reported in the Journal of ...  Oct 10, 2006
Lung Rx, Inc., a wholly owned subsidiary of United Therapeutics Corporation, announced the publication of "Safety and Efficacy of Inhaled Treprostinil as Add ... -DG News Results Of Inhaled Treprostinil Study Reported In The Journal Of ...  Oct 11, 2006
Announced the publication of "Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension" in the current ... -PipelineReview.com (press release), United Therapeutics Announces Share Repurchase Program, Third ...  Oct 27, 2006
130 patients have been enrolled in United Therapeutics' TRIUMPH-1 trial, a 200-patient 12-week placebo-controlled trial of inhaled treprostinil in pulmonary ... -Drug Newswire (press release), Buyback Buoys United Therapeutics  Oct 23, 2006
...fund the buyback. The company also said 130 patients have enrolled in a 200-patient trial of inhaled treprostinil. The Silver Spring ... -TheStreet.com United Therapeutics Reports Third Quarter 2006 Financial Results  Oct 31, 2006
The increase was primarily due to increased expenses for treprostinil-related programs of approximately $578,000 and the adoption of SFAS No. ... -Earthtimes.org (PRN) - Momenta Pharmaceuticals Commences Phase I Clinical Study ...  Oct 10, 2006
Sclerosis ... [+. PRN) - Results of Inhaled Treprostinil Study Reported in the Journal of the American College of Cardiology ... [+. ... -Bolsamania.com, Biogen Idec Licenses PAH Drug From MondoBiotech  Sep 14, 2006
The product is an oral formulation of treprostinil, the active ingredient in UTC's Remodulin, approved for subcutaneous and intravenous treatment of PAH. ... -BioWorld Online

United Therapeutics Affiliate Initiates First-Ever Gene-Therapy ...  -  12 Dec 2006
Drug Newswire (press release),...have been enrolled in its TRIUMPH-1 trial, a 200-patient 12-week placebo-controlled trial of inhaled treprostinil in pulmonary arterial hypertension.

United Therapeutics Q2 Earnings Falls; Misses Estimate - Update  Aug 1, 2006
...and development expenses increased to $12.6 million from $8.7 million in the year ago quarter, due to increased expenses for treprostinil-related programs. ... -Trading Markets

Biotech's shares decline 12 percent  Aug 2, 2006
The company said it is behind schedule in trials for the inhaled treprostinil because clinics can't find enough patients to enroll: Competitors are taking them ... -Baltimore Sun

United Therapeutics Reports Second Quarter 2006 Financial Results  Aug 1, 2006
The increase was due primarily to increased expenses for treprostinil-related programs of approximately $2.0 million, implementation of SFAS No. ... -PR Newswire



FDA Approves Expanded Label Indication and Satisfaction of Subpart ...  Mar 21, 2006
...the United States Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Remodulin(R) (treprostinil sodium) Injection. ... - DG News

PAH: market ripe for expansion as big pharma interest increases  Mar 27, 2006
...interest was sparked by the launch of three new therapies and formulations in the US - United Therapeutics' IV Remodulin (treprostinil), CoTherix' Ventavis ... - Pharmaceutical Business Review

Encysive Shares Tumble On FDA Thelin Approvable Letter  Mar 27, 2006
Other therapies for the condition include the prostacyclins Remodulin (treprostinil sodium, from United Therapeutics Corp.) and the inhaled Ventavis (iloprost ... - BioWorld Online (subscription)

United Therapeutics' Remodulin study OK'd  Mar 21, 2006
The company also said it has also been granted expanded labeling for its treprostinil sodium injection, indicated for the treatment of pulmonary arterial ... - United Press International

FDA approves United Therapeutics' Remodulin label expansion  Mar 23, 2006
...of the FDA's Subpart H accelerated approval requirement for a phase IV post-marketing study to confirm the clinical benefit of Remodulin (treprostinil sodium). ... - Pharmaceutical Business Review

Imperial School of Medicine, National Heart and Lung Institute ...  Mar 9, 2006
...with congenital heart or connective tissue disease) started bosentan with or without concomitant intravenous epoprostenol or subcutaneous treprostinil therapy. ... - AJRCCM (subscription)

International Approvals: Tasmar, Amplimexon, IV Remodulin  Jan 17, 2006
Commission has approved orphan drug status for imexon injection in the treatment of ovarian cancer; and Israel has approved treprostinil sodium injection for ... - Medscape (subscription)

Israeli Ministry of Health Approves Intravenous Dosing of ...  Jan 10, 2006
...announced today that the Drug Registration Department of the Israeli Ministry of Health has expanded the label of Remodulin(R) (treprostinil sodium) Injection ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional